Top News
- Takeda and Insilico partner on AI-driven drug discovery with deal valued up to $600M
Insilico providing AI platform to help Takeda identify novel targets across multiple therapeutic areas.
Inocras partners with AimedBio to leverage whole-genome intelligence for cancer drug developmentStrategic collaboration aims to enhance oncology pipeline using genomic data integration across development programs.
Can-Fite's phase IIa data in pancreatic cancer drives stock up 58% amid PDAC therapeutic momentumIsraeli biotech reports encouraging results in hard-to-treat ductal adenocarcinoma; shares closed at $4.71 on July 1.
Novo Nordisk's largest shareholder invests in Italian life science startup accelerator to expand drug development beyond DenmarkMove signals effort to build early-stage biotech ecosystem across Europe beyond Novo's Nordic home base.
Zimmer Biomet acquires Pacira's Iovera cryotherapy system for up to $140M in med-tech tuck-in trendDeal reflects broader consolidation as larger players acquire niche pain-management and diagnostics assets.
Sanofi's Nexviazyme meets primary endpoints in Baby-COMET trial; label expansion in younger Pompe disease patients on trackEnzyme replacement therapy showed efficacy in pediatric cohort; potential to extend current indication.
Ipsen acquires Memo Therapeutics for €700M ($797M) to add phase III kidney transplant antibody to portfolioPotravitug targets BK virus-associated nephropathy in immunocompromised transplant patients; Ipsen's second acquisition this week.
More: BioPharma Dive
FDA approves Orca Bio's Tregzi, first T-cell therapy engineered to reduce graft-versus-host disease in stem cell transplant patientsPrecision-engineered cell therapy designed to improve outcomes in allogeneic HSCT for hematologic malignancies.
EMA CHMP adopts positive opinion for upadacitinib in severe alopecia; EU approval expectedJanus kinase inhibitor recommended for adult and adolescent patients with severe hair loss.
- AlzeCure Pharma partners with QuantumCell in $2.2B licensing deal for Alzheimer's platform
Lead candidate has already shown positive Phase I data; QuantumCell gains exclusive rights to AlzeCure's platform.
- Flare Therapeutics closes $85M Series C, consolidates pipeline around first-in-class AR-ON degrader FX-111
Flare narrows focus to lead program after strategic review following $85M financing round.
- Novo Nordisk's Wegovy becomes available to eligible Medicare beneficiaries through GLP-1 Bridge program
Expands access to semaglutide for weight loss in seniors as Medicare coverage debate continues.
Hong Kong biotech IPO activity accelerates with three Chinese companies raising HK$4.7B in JuneAlebund, Longbio, and Shaanxi Micot débuts signal renewed investor appetite for Asian biotech in secondary markets.
Chinese-made magnetically levitated heart pump advances in US clinical use despite biotech decoupling pressuresDevice is smaller than a table tennis ball; raises questions about supply-chain resilience amid US-China tech restrictions.
Telum Therapeutics raises €18M Series A to advance antimicrobial targeting multidrug-resistant Acinetobacter baumanniiSpanish biotech funds development of novel antibacterial for hospital-acquired pneumonia and ventilator-associated infections.
Andy Hill Cancer Research Endowment awards Aptevo $1.5M grant for trispecific antibody APVO-451 in solid tumorsGrant funds IND-enabling studies for Aptevo's multispecific immunotherapy entering clinical development.
Real-world evidence from 12-month study supports safety and efficacy profile of AbbVie's Vyalev in Parkinson's diseaseEAN 2026 data demonstrates Vyalev's performance in routine clinical practice beyond controlled trial settings.
MED-EL acquires two gene therapy programs from Rescue Hearing for genetic hearing and balance disordersMED-EL expands otology pipeline through acquisition of preclinical gene therapy assets.
FDA rejects Unicycive Therapeutics' resubmitted NDA for OLC to treat hyperphosphatemia in dialysis patients with chronic kidney diseaseComplete Response Letter marks second regulatory setback for the oral phosphate binder candidate.
Eli Lilly partners with Innovent Biologics to commercialize Verzenios in mainland ChinaCDK4/6 inhibitor Verzenios expands into one of world's largest cancer drug markets through local licensing deal.
AWS provides multimillion-pound cloud and AI support to Fleming Initiative's antimicrobial resistance research programAWS contribution includes cloud infrastructure, AI tools, and technical expertise to accelerate AMR drug discovery and development efforts.
AbbVie presents Phase III ECLIPSE data for EU-approved Aquipta in acute migraine at EAN 2026First clinical efficacy readout since European regulatory approval; results shown at Congress of the European Academy of Neurology.
Ipsen to acquire Kartos Therapeutics for $450M to gain late-stage myelofibrosis asset fasedienolFDA simultaneously launches pre-check pilot program to streamline drug reviews; Sobi faces regulatory setback on blood cancer candidate.
Anthropic to develop drugs in-house, expanding AI company into therapeutic developmentMove marks major AI player's entry into biotech; unclear whether company will retain full ownership or partner with pharma operators.
House Select Committee on China investigates US drugmakers' clinical trials at Chinese military hospitals and in XinjiangProbe focuses on potential national security and ethical concerns around trial conduct in sensitive PRC locations.
More: Pharmaceutical Executive